BioLight Life Sciences Ltd. BOLT

Vancouver, British Columbia--(Newsfile Corp. - August 31, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce it will be proceeding with a non-brokered private placement of up to 2,800,000 units ("Units") at a price of C$0.50 per Unit for aggregate gross proceeds of up to C$1,400,000 (the "Offering"). The Company expects BioLight Life Sciences Ltd., parent company of DiagnosTear, and Elcam Medical Ltd. to each participate for up to.

As most Gulf stock markets gain on the prospects of a U.S. rate cut, investor sentiment in the Middle East is buoyed by potential monetary easing and its implications for regional economies. Penny stocks, a term that may seem outdated, continue to capture interest due to their unique blend of affordability and growth potential. These smaller or newer companies can offer promising opportunities when supported by strong financials, making them an intriguing option for investors seeking...